Ocugen Inc (OCGN)stock report

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Finance:
Market Cap:30.5M; Shares Outstanding:52.6M; Short Interest: 23.30%;
no financial data available

EPS and Sales:
https://finance.yahoo.com/quote/OCGN/financials?p=OCGN

Insider Transactions:
http://insidercow.com/history/company.jsp?company=OCGN&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/OCGN/institutional-ownership/

2019.12.31:
Total institutions: 28,no change
Shares hold: 650.8k shares. no change
shares% hold: 4.07%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/OCGN/price-targe

Leave a Reply